Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

APG2575: This study is evaluating how safe, tolerable and effective targeted therapy in combination with chemotherapy is in people with acute myeloid leukaemia, mixed phenotype acute leukaemia, chronic myelomonocytic leukaemia and higher-risk myelodysplastic syndromeA Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

This trial is evaluating a targeted therapy called APG-2575 in combination with chemotherapy (azacitidine), and will be run in two stages. In the first stage (dose escalation), cohorts of participants will receive APG2575 in escalating doses in combination with azacitidine. Once the maximum tolerated dose and recommended phase 2 dose of APG-2575 has been established, the safety and effectiveness of this dose when given in combination will be further evaluated in stage two (dose expansion).

Treatment Type

Radiotherapy,Systemic therapy (chemotherapy, hormone therapy or immunotherapy)

Age

People 18 - 99

Phase

I/II

Trial Acronym

APG2575

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04964518
APG2575AU101

Commercial Sponsor

Ascentage Pharma Group Inc.

Scientific Title

A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have been diagnosed with a prior or secondary type of cancer.
You have had certain treatments, surgical procedures or drugs.

Exclusion

You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You have had treatment, but your cancer has come back.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy